

# MODULATION OF THE MICROBIOTA-GUT-BRAIN AXIS AS A THERAPEUTIC STRATEGY FOR ALZHEIMER AND PARKINSON'S DISEASE

H. Ceuleers<sup>1,2</sup>, T. Breugelmans<sup>1,2</sup>, W. Arras<sup>1,2</sup>,  
B.Y. De Winter<sup>1,2,3</sup>, A. Smet<sup>1,2</sup>

<sup>1</sup>Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium

<sup>2</sup>Infla-Med Research Consortium, University of Antwerp, Antwerp, Belgium

<sup>3</sup>Gastroenterology and Hepatology Department, Antwerp University Hospital, Antwerp, Belgium

Corresponding Author: Hannah Ceuleers, PhD; e-mail: hannah.ceuleers@uantwerpen.be

**Abstract:** Targeting the gut microbiota as part of the microbiota-gut-brain axis has been proposed as a potential interesting new therapeutic strategy for neurodegenerative disorders, such as Parkinson's and Alzheimer's disease. In this review, the original articles from April 2020 to March 2021 tackling this research topic, are discussed. Multiple research groups investigated the mechanisms involved in the altered microbiota-gut-brain axis in Parkinson's and Alzheimer's disease, pointing out correlations between the gut microbiome and specific (patho)physiological properties or gastrointestinal functions and the potential of gut microbial markers as novel diagnostic biomarkers. Furthermore, the interventions described to target the gut microbiota, included probiotics (e.g., VSL#3, *Bifidobacterium* strains), prebiotics (e.g., plant and yeast extracts), supplements (e.g., minerals), medication (e.g., acetylcholine esterase inhibitors, antibiotics) and alternative therapies (e.g., acupuncture). Positive effects on the different components of the microbiota-gut-brain axis were demonstrated, such as an improvement of gut microbiota dysbiosis (including a restoration of the *Bacteroidetes* to *Firmicutes* ratio, a decrease in *Clostridiales*, and an increase in *Lactobacillus* and short-chain fatty acids), intestinal barrier dysfunction, inflammation (central/systemic/intestinal), motor deficits, cognitive impairment, neurotoxicity, pathological lesions in the brain, and amyloid  $\beta$  (A $\beta$ ) deposition. These results show a major role for the modulation of the microbiota-gut-brain axis as a new therapeutic strategy for both Parkinson's and Alzheimer's disease. Since the available data predominantly resulted from preclinical studies, future research should be focused on translational studies with a bench-to-bedside approach in order to eventually incorporate new treatments targeting the microbiota-gut-brain axis in the clinic.

**Keywords:** Microbiota-gut-brain axis, Mechanism, Biomarker, Animal models, Probiotics, Prebiotics, Supplements, Parkinson's disease, Alzheimer's disease.

## INTRODUCTION

The concept of the gut-brain axis, encompassing the bidirectional communication between the nervous system and the gastrointestinal tract, has long been acknowledged. Furthermore, evidence has also been provided for the involvement of the microbiota as one of the key regulators of gut-brain function which led to the appreciation of the importance of a distinct microbiota-gut-brain axis. Preclinical and clinical studies revealed exciting potential for novel treatments targeting the gut microbiota in neurodegenerative diseases such as Parkinson and Alzheimer's disease<sup>1</sup>.



This work is licensed under a [Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License](https://creativecommons.org/licenses/by-nc-sa/4.0/)

## MATERIALS AND METHODS

A literature search was performed on PubMed with the following search terms: “microbiota” AND “gut” AND “brain” AND “Alzheimer” OR “Parkinson”. Results were limited to research articles published between April 2020 and March 2021. The following inclusion criteria were used: (1) studies in English and (2) only original research papers (no reviews). Based on these criteria, 47 studies were eventually included in this review.

## PARKINSON'S DISEASE

Parkinson's disease (PD) is a neurodegenerative disease with an increasing prevalence worldwide. It is characterized by the presence of bradykinesia combined with either rest tremor and/or rigidity, as well as non-motor symptoms, such as gastrointestinal complaints. The pathophysiology encompasses a complex interplay of aberrant  $\alpha$ -synuclein aggregation, dysfunction of mitochondria, lysosomes or vesicle transport, synaptic transport issues, and neuroinflammation. The current first-line therapy consists of levodopa, but a treatment that can slow down or stop the progression of PD has yet to be found. This highlights the need for further research towards new therapeutic strategies and a more personalized treatment of PD patients<sup>2</sup>. Hence, the role of the microbiota-gut-brain axis in PD has been intensively studied, both in animals and humans.

### Mechanistic Studies

Dendritic cell factor 1 (Dcf1) is a membrane protein that plays a key role in the development of the nervous system. Li et al<sup>3</sup> highlighted that the changes observed in the gut microbiota of Dcf1<sup>-/-</sup> knockout (KO) mice compared to wildtype animals were similar to the human situation in PD patients, with an increase in *Proteobacteria* (phylum-level) and a decrease in *Prevotellaceae* (family-level). More specifically, on a species level, a decline in *Prevotellaceae* UCG-001 and a rise in *Helicobacter ganmani* was observed in KO mice, which associated with glycolipid metabolism disorders and inflammatory lesions, respectively. Furthermore, Dcf1<sup>-/-</sup> mice showed typical PD-like behavioral and pathological changes<sup>3</sup>. The gut microbiota in PD patients was also investigated using metagenomics and serum metabolomics, uncovering the contribution of the gut microbiome to the degradation of mucin and host glycans, folate deficiency and homocysteine metabolism in PD patients<sup>4</sup>. Previous studies<sup>5,6</sup> have demonstrated that short-chain fatty acids (SCFA) are reduced in fecal samples of PD patients. Surprisingly, a more recent study from Shin et al<sup>7</sup> reported that an increase in plasma SCFA in PD patients was associated with disease severity and anti-PD medication. Other studies<sup>8</sup> reported correlations between gut microbiota alterations and specific (patho)physiological functions. Firstly, gut microbiota dysbiosis, as characterized by elevated *Peptostreptococcaceae*, *Lachnospiraceae* and *Burkholderiales* and a decline in *Methanobacteriales*, *Odoribacter*, *Clostridium*, unclassified *Sutterellaceae* and *Escherichia*, resulted in increased bile acids in PD patients<sup>8</sup>. An increase in *Ruminococcus*, *Parabacteroides* and *Parasutterella* and a decrease in *Coriobacteriaceae*, *Flavonifractor*, *Lachnospiraceae*, *Lactobacillaceae*, and *Rikenellaceae*, was correlated with the disturbance of specific neurotransmitter pathways (dopamine, kynurenine, serotonin) in an 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPT-P)-induced PD mouse model<sup>9</sup> whereas a reduction of the *Clostridium* genus associated with the genetic variant of the bitter taste receptor TAS2R38 (a genetic risk factor for the development of PD) in PD patients, possibly resulting in reduced activation of protective signaling molecules and thus gut homeostasis<sup>10</sup>. Furthermore, two studies<sup>11,12</sup> demonstrated an association between gut microbiota alterations on the one hand and gastrointestinal functions on the other hand. In a rotenone-induced conventional PD model, an increase in the bacterial genera *Lactobacillus*, *Bifidobacterium*, *Akkermansia*, and *Bacteroides* spp. and a decrease in *Lachnospiraceae*, *Ruminococcaceae* UCG-014, *Turicibacter*, *Faecalibaculum*, and *Clostridium* spp was observed. These changes in gut microbiota composition could be linked to an increased intestinal permeability and motor deficits, which were only observed in rotenone-treated conventionally-raised mice and not in rotenone-treated germ-free mice<sup>11</sup>. The second study<sup>12</sup> in PD patients identified microbial alter-

ations characterized by a higher abundance of *Christensenellaceae*, *Desulfovibrionaceae*, *Bifidobacterium*, *Collinsella*, *Bilophila* and *Akkermansia* and a lower abundance of *Lachnospiraceae*, *Roseburia*, an unclassified *Lachnospiraceae* genus and *Faecalibacterium*. These shifts in microbial composition strongly associated with stool consistency and constipation in PD patients<sup>12</sup>. Also, the effect of two common infections was tested in different PD mouse models. An oral infection with *Porphyromonas gingivalis* (the most common bacterium causing periodontitis) in leucine-rich repeat kinase 2 (LRRK2)-mutated PD mice resulted in an inflammatory response, an altered intestinal permeability and neurodegenerative lesions, such as a decline in dopaminergic neurons in the substantia nigra and activated microglial cells<sup>13</sup>. Cannon et al<sup>14</sup> characterized the intestinal microbiota during a *Citrobacter rodentium* infection in a Pink1<sup>-/-</sup> KO mouse model for PD, with no major differences in fecal microbial diversity but a remarkable increase in the SCFA butyric acid at the peak of infection and post infection. Of note, butyric acid levels were not different in WT vs. Pink1<sup>-/-</sup> KO mice prior to infection. These results contrast to the findings in humans, where fecal butyric acid levels in PD patients are lower<sup>14</sup>. Finally, two studies<sup>15,16</sup> identified novel gut microbial factors as potentially interesting diagnostic biomarkers for PD. More specifically, Qian et al<sup>15</sup> identified 25 gut microbial gene markers distinguishing PD patients from healthy controls (ROC curve: AUC 0.896, confidence interval: 83.1-96.1%), as well as discriminating between PD and multiple system atrophy and between PD and Alzheimer's disease<sup>15</sup>. The 25 microbial gene markers consist of different species from the genera *Bacteroides*, *Escherichia*, *Enterobacteriaceae*, *Proteobacteria*, *Klebsiella*, *Akkermansia* and *Alistipes*. For a complete overview, we refer to the Supplementary Table 12 published by Qian et al<sup>15</sup>. Another study<sup>16</sup> identified a subset of 22 bacterial families (*Lachnospiraceae*, *Ruminococcaceae*, *Bacteroidaceae*, *Verrucomicrobiaceae*, *Rikeillaceae*, *Bifidobacteriaceae*, *Porphyromonadaceae*, *Veillonaceae*, *Enterobacteriaceae*, *Alcaligenaceae*, *Christensenellaceae*, *Streptococcaceae*, *Erysipelotrichaceae*, *Odoribacteriaceae*, *Prevotellaceae*, *Desulfovibrionaceae*, *Coriobacteriaceae*, *Clostridiaceae*, *Barnesiellaceae*, *Lactobacillaceae*, *Tissierellaceae*, *Streptococcaceae*) to predict PD by using machine learning algorithms analyzing 846 metagenomic samples from PD patients and healthy controls<sup>16</sup>.

## Intervention Studies

Other studies have investigated whether specific interventions targeting the microbiota-gut-brain axis could affect PD symptoms in different animal models.

The effect of probiotics in PD animal models showed predominantly positive effects on PD pathology in different studies. A 4-week oral treatment of MPTP-induced PD mice with *C. butyricum* improved motor deficits and neurotoxicity and reversed gut microbiota dysbiosis<sup>17</sup>. Similar results were observed after a 4-week oral treatment with *L. plantarum* PS128 in MPTP-induced PD mice<sup>18</sup>. Also, a 4-day oral administration of *B. breve* strain A1 in MPTP-induced mice resulted in an enhanced cognitive performance, as demonstrated by a restored abnormal hippocampal synaptic plasticity and the facilitation of fear extinction<sup>19</sup>. Exposure of rats to manganese (a transition metal) resulted in neurotoxicity, as demonstrated by an increased A $\beta$  and Tau production in the brain, hippocampal degeneration and necrosis, which could be improved after manganese-exposed rats received a fecal microbiota transplantation (FMT) from normal rats<sup>20</sup>. Furthermore, oral gavage of *Enterococcus faecalis* or *E. faecium* in an MPTP + probenecid (medication that increases uric acid excretion in the urine) mouse model increased brain dopamine and ameliorated PD manifestation whereas supplementation with oral berberine (a phytonutrient) even showed a better therapeutic effect than with bacteria alone<sup>21</sup>. This interesting therapeutic effect could be explained by the fact that *Enterococcus* administration resulted in the synthesis of dopa/dopamine in the intestinal tract, thereby elevating dopamine levels in the blood and brain. Moreover, berberine is an agonist of tyrosine hydroxylase in *Enterococcus* and the combination of *Enterococcus* with berberine could thereby lead to the production of L-dopa in the gut and an amelioration of PD symptoms. This study<sup>21</sup> suggests that *E. faecalis* and *E. faecium* might ameliorate PD symptoms via dopa/dopamine production in the intestine, and that drug regulation of this process might further improve brain function. On the other hand, a pre-treatment with the probiotic VSL#3 (containing *Bifidobacteria*, *Lactobacillus*, *Streptococcus thermophilus* BT01) did not influence the PD-like pathology provoked by a dual hit toxin model using lipopolysaccharide (LPS) and

paraquat exposure<sup>22</sup>. Taken together, these studies suggest the potential of probiotics to improve PD pathological symptoms, such as motor and cognitive impairment, neurotoxicity and gut microbiota dysbiosis.

Prebiotics are also seen as a possible therapeutic option for PD patients. The plant flavonoid fisetin was demonstrated to have neuroprotective effects in an MPTP-induced PD mouse model by altering the number, diversity and distribution of gut microbiota<sup>23</sup>. More specifically, the *Lachnospiraceae* family was more abundant whereas the *Bifidobacteriaceae*, *Enterobacteriaceae* and *Bacillaceae* families were depleted. At the genus level, the treated animals displayed an increase in *uncultured\_bacterium\_f\_Lachnospiraceae*, *[Eubacterium]\_ruminantium\_group*, and *Marvinbryantia*, and a decrease in *Bifidobacterium*, *Escherichia*, *Shigella* and *Bacillus*<sup>23</sup>. Neuroprotective effects were also observed after a 2-month oral treatment of 6-hydroxydopamine-induced PD mice with propionate or its receptor agonist (FFAR3-agonist, AR420626)<sup>24</sup>. Furthermore, a 4-week oral preventive treatment with the brown seaweed polysaccharide of polymannuronic acid (chosen for its low toxicity and easy biodegradability) showed neuroprotective effects (i.e., improved motor functions by preventing dopaminergic neuronal loss in the substantia nigra and increased levels of striatal neurotransmitters) in the same PD mouse model<sup>25</sup>. In addition, inflammation was significantly reduced in the gut, brain and systemic circulation and the integrity of the intestinal barrier and the blood brain barrier was enhanced. Treatment also resulted in an altered gut microbiota composition, with a suppression of *Lactobacillus* and *Turicibacter* and an increase in *Coprococcus* and *Ruminococcus*, which were respectively increased and decreased in untreated MPTP-mice. Finally, also alterations in the digestion and metabolism of dietary proteins and fats were noticed, leading to an increased level of SCFA (total SCFA, acetic acid, propionic acid and butyric acid) in the colon<sup>25</sup>. The abovementioned studies clearly highlight the beneficial effects of prebiotics on different parts of the microbiota-gut-brain axis in PD-like pathology, as shown by an improvement of the gut microbiota composition, neurotoxicity, inflammation, intestinal and blood brain barrier.

The mercury-sulfide-containing supplements Hua-Feng-Dan and 70 Wei-Zhen-Zhu-Wan (Rannasangpei) showed promising results in an MPTP + lipopolysaccharide (LPS)-induced two-hit PD mouse model<sup>26</sup>. More specifically, treatment improved motor activity and ameliorated pathological lesions in the brain (microglia and dopaminergic neurons), as well as altered the gut microbiota composition, which was characterized by a depletion of *Verrucomicrobiaceae*, *Methanobacteriaceae*, *Pronicromonosporaceae* and *Clostridaceae*<sup>26</sup>. Mercury sulfide is presumed to assist therapeutic effects of other ingredients in polyherb-metallic preparations<sup>26</sup>. Similar results were observed in an MPTP mouse model after a 12-day oral treatment with Korean red ginseng. In this study, beneficial effects were observed on motor activity, brain lesions and the gut microbiota composition, typified by a lower abundance of *Verrucomicrobiaceae*, *Ruminococcus* and *Akkermansia* and an increased abundance of *Eubacterium*<sup>27</sup>. A 2-month intraperitoneal treatment with osteocalcin (protein secreted by osteoblasts) ameliorated motor deficits and dopaminergic loss in a 6-hydroxydopamine-induced PD mouse model, which was mediated by propionate-producing gut microbiota<sup>24</sup>.

Other therapeutic options include, e.g., acupuncture treatment, which was demonstrated to improve motor functions and anxiety, protected dopaminergic neurons as well as alter gut microbiota composition in MPTP-induced PD mice<sup>28</sup>. 16S rRNA sequence analysis further revealed a significant enrichment of *Rikenellaceae*, *Vallitaleaceae*, *Alistipes*, *Vallitalea*, *Lachnoclostridium*, *Pseudoclostridium*, *B. xylanolyticus*, *V. pronyensis*, *C. aerotolerans*, *P. thermosuccinogenes* and *R. faecis*. Some of them were even correlated with motor functions and/or anxiety<sup>28</sup>.

## ALZHEIMER'S DISEASE

Alzheimer's disease (AD) is a chronic neurodegenerative disorder with an estimated prevalence of 10-30% in the population of >65 years. The underlying disease mechanism consists of the failure to clear A $\beta$  from the interstices of the brain. The FDA-approved medication results in symptom improvement, but it does not affect the underlying disease mechanisms, thereby highlighting the need for novel therapeutic targets. The modulation of the microbiota-gut-brain axis is one possibility, that has received increased attention in the latest years<sup>29</sup>.

## Mechanistic Studies

Multiple studies have investigated associations between the gut microbiota composition and some typical pathophysiological features of AD. A mouse study demonstrated a sex-dependent relationship between the gut microbiota composition (with a decreased abundance of *Ruminococcaceae*) and cognitive dysfunction, which was only observed in female transgenic AD mice<sup>30</sup>. Interestingly, another research group also reported gender-dependent differences in APP/PS1 transgenic mice. They found that the bile acid (BA) profile (based on the levels of 28 different BAs) was significantly different in male compared to female mice, with decreased levels of taurine-conjugated primary BAs (i.e., tauroursodeoxycholic acid, taurocholic acid and muricholic acid) and increased levels of secondary BA (iso-deoxycholic acid) in plasma and liver extracts in female mice. In contrast, increased levels of taurodeoxycholic acid in liver extracts and decreased levels of muricholic acid in jejunal content were observed in male AD mice<sup>31</sup>. Of note, sex differences are also observed in the epidemiology of Alzheimer's disease in humans<sup>32</sup>. Another study<sup>33</sup> demonstrated an altered composition of intestinal bacterial communities in 5-month-old APP<sup>swe</sup>/PS1<sup>ΔE9</sup> (PAP) transgenic mice characterized by an upregulation of *Acinetobacter guillouiae* and *B. coprocola* and a downregulation of *C. methylpentosum*, *Aminipila butyrlica*, *Lawsonibacter asaccharolyticus*, *Kineothrix alysoides*, *Flintibacter butyricus* and *A. finegoldii*. These microbial changes in the gut of 5-month-old PAP mice were correlated with the impairment of cognitive functioning and might stimulate amyloid deposition by promoting the MAPK signaling pathway in the brain. Besides, two different mouse studies showed the occurrence of gut microbial changes before the presence of typical features of AD. Chen and colleagues demonstrated the presence of differences in microbiome composition between WT and APP/PS1 starting from an early age and increasing with age. Of note, WT and their age-matched WT littermates were housed together under specific pathogen-free conditions (n=4 mice/cage). Specifically, at 2 months of age, there was already an increased abundance in APP/PS1 mice compared to age-matched WT mice of the phyla *Verrucomicrobia*, *Actinobacteria* and *Proteobacteria* and the families *Verrucomicrobiaceae*, *Prevotellaceae*, *Erysipelotrichaceae*, and *Bifidobacteriaceae*. At the genus level, *Akkermansia*, *P. UCG-001*, *Bifidobacterium*, *Erysipelatoclostridium*, *Allobaculum* and *Alloprevotella* were significantly elevated. At later ages (i.e., 6 and 9 months), inflammation-related bacterial taxa such as *Escherichia*, *Shigella*, *Desulfovibrio*, *Akkermansia*, and *Blautia* were more abundant in APP/PS1 mice compared to age-matched WT mice. Interestingly, key pathological features of AD, such as amyloid deposition and plaque-localized neuroinflammation, were only seen at later ages, starting at 3 months, thereby indicating that microbial alterations in the gut precede typical pathological features of AD<sup>34</sup>. A second study proposed a possible mechanism behind the gut microbial alterations eventually leading to AD. In brief, Wei et al<sup>35</sup> found that outer membrane vesicles, produced by gut microbiota, could increase the blood brain barrier permeability and activate astrocytes and microglia, thereby inducing an inflammatory response and tau hyperphosphorylation by stimulating the GSK-3 pathway, eventually leading to cognitive dysfunction<sup>35</sup>. Another research group demonstrated an altered microbial composition in APP/PS1 mice after chronic noise exposure with a decrease of *Muribaculaceae* and an increase of *Bacteroidaceae* at the family level, as well as decreased levels of *Rikenella* and *Anaerovorax* at the genus level. These microbial alterations were related to detrimental effects on oxidation, systemic inflammation and tight junction expression levels in the brain and intestines<sup>36</sup>.

## Intervention Studies

Research in the field of AD has also been dedicated to the effects of specific interventions targeting the microbiota-gut-brain axis in animal models and humans.

The effect of probiotics has also been investigated in AD. A 6-month oral treatment of APP/PS1 double transgenic mice with *B. longum* 1714 resulted in a reduced A $\beta$  deposition in the brain, a reduced microglial activation and reduced levels of pro-inflammatory cytokines in the brain<sup>37</sup>. Interestingly, these positive results were confirmed in a randomized double-blind, and placebo-controlled multicenter trial in healthy 65+ volunteers that were

treated with *Bifidobacterium* strains, including *B. bifidum* BGN4 and *B. longum* BORI, for 12 weeks. Compared to the placebo group, the treated group showed a greater improvement in the mental flexibility test and stress score, a significant reduction in inflammation-causing gut bacteria (*Eubacterium*, *Allisonella*, *Clostridiales*, and *Prevotellaceae*), a significant increase in brain-derived neurotrophic factor (BDNF) serum levels which were negatively correlated with *Eubacterium* and *Clostridiales*<sup>38</sup>. Food containing seven different lactic acid bacteria strains reversed the malformation of eye structures (frequently observed in AD) in the transgenic GMR-A $\beta$ 42 *Drosophila melanogaster* animal model. Moreover, these lactic acid bacteria ameliorated the gut microbiota profile with a reduction of *Wolbachia* and an increase of *Stenotrophomonas* and *Acetobacter* (resembling the microbial profile of the control group)<sup>39</sup>. Probiotic supplementation of App<sup>NL-G-F</sup> mice with VSL#3 resulted in a significant increase in both bacterial diversity and species richness, with an increased abundance of the bacteria phyla *Verrucomicrobia* and *Actinobacteria*, but no change in the overall *Firmicutes/Bacteroidetes* ratio. Furthermore, a decreased intestinal inflammation and gut permeability as well as minimal effects on A $\beta$ , cytokine and gliosis levels in the brain were observed<sup>40</sup>. Finally, the clinical relevance of FMT in AD was demonstrated in a case report showing symptom improvement in a patient with AD following FMT for treating a *C. difficile* infection<sup>41</sup>. Altogether, these studies suggest an interesting role for probiotics as a therapeutic option for AD patients with favorable effects on A $\beta$  deposition and inflammation in the brain, microglial activation, gut microbiota composition and even intestinal inflammation and barrier function.

The prebiotic R13 (7,8-Dihydroxyflavone prodrug) had positive effects, when given once a day from 12 weeks of age through 24 to 25 weeks of age in a 5XFAD mouse model. More specifically, it suppressed amyloid aggregates in the gut, alleviated gut dysbiosis and induced probiotic *L. salivarius* that suppressed C/EBP $\beta$ /AEP signaling, thereby decreasing gut leakage and oxidative stress<sup>42</sup>. Also yeast  $\beta$ -glucans administration in A $\beta$ <sub>1-42</sub>-induced AD mice resulted in alterations of the composition of the gut microbiota. At the phylum level, it restored the Bacteroidetes to Firmicutes ratio. At the genus level, inflammatory-related bacteria such as *Oscillibacter*, *Mucispirillum*, *Alistipes*, *Anaerotruncus*, *Rikenella* were decreased whereas beneficial bacteria such as *Lactobacillus*, *Bifidobacterium*, *Saccharibacteria\_genera\_incertae\_sedis* and *Desulfovibrio* increased. Besides, yeast  $\beta$ -glucans ameliorated cognitive defects (by alleviating neuroinflammation and brain insulin resistance), increased SCFA levels and restored gut microbiota dysbiosis<sup>43</sup>.

The effects of different supplements were also investigated in preclinical mouse and rat models for AD. *Poria cocos* (a wood-decay fungus) improved the cognitive function, reduced A $\beta$  deposition and improved gut dysbiosis in APP/PS1 mice<sup>44</sup>. Similar effects were observed after supplementation with salidroside (a plant extract) in SAMP8 mice<sup>45</sup>, quercetin-3-O-glucuronide in A $\beta$ <sub>1-42</sub>-induced AD-like mice<sup>46</sup>, *Tetragonia tetragonioides* Kuntze (TTK; New Zealand spinach) A $\beta$ <sub>25-35</sub>-induced rats<sup>47</sup> and Camellia oil in aluminium chloride-treated rats<sup>48</sup>. With regard to the improved gut dysbiosis, salidroside restored the Bacteroidetes to Firmicutes ratio and reduced both *Clostridiales* and *Streptococcaceae*<sup>45</sup>. Similarly, quercetin-3-O-glucuronide supplementation also restored the *Bacteroidetes* to *Firmicutes* ratio and elevated short-chain fatty acids (SCFA)<sup>46</sup>. Administration of TTK resulted in a reduction of *Clostridiales*, *Erysipelotrichales*, *Desulfovibrionales* and an increase in *Lactobacilales* and *Bacteroidales*<sup>47</sup>. *Lactobacilales* were also increased after treatment with Camellia oil<sup>48</sup>. Interestingly, these supplements also exerted other specific effects. Quercetin-3-O-glucuronide and TTK improved insulin signaling and ameliorated insulin resistance in the brain<sup>46,47</sup>. Moreover, salidroside and camellia oil attenuated pro-inflammatory cytokine expression levels in the blood and brain<sup>45,48</sup>. In addition, salidroside improved intestinal barrier homeostasis and reduced microglial activation<sup>45</sup>, whereas camellia oil also decreased multiple AD-related proteins (APP, BACE1 and TAU-5), enhanced antioxidant enzyme levels and the expression of autophagy-related proteins (Atg5, Beclin-1, and LC3II)<sup>48</sup>.

On the contrary, two other supplements, trimethylamine N-oxide (TMAO; a gut microbe-dependent metabolite)<sup>49</sup> and wheat amylase trypsin inhibitors (ATIs) (dietary protein component of gluten-containing cereals)<sup>50</sup> both aggravated AD pathology in a 3xTg and a 5xFAD AD mouse model, respectively. At the gut microbial level, ATIs induced a lowered *Bacteroidetes* to *Firmicutes* ratio and a reduction in *Bifidobacteria*<sup>50</sup>. These data point towards TMAO inhibition and an ATI-depleted diet as potential therapeutic options<sup>49,50</sup>.


Finally, the effects of some classic medication were also investigated in preclinical mouse models for AD. Both a 3-week subcutaneous treatment with anastrozole (27-hydroxycholesterol inhibitor) and an oral treatment from postnatal day 14-21 with an antibiotic cocktail (containing kanamycin, gentamicin, colistin, metronidazole, vancomycin) in APP/PS1 transgenic mice significantly reduced the brain A $\beta$ -amyloidosis and altered the microbiota profile<sup>51,52</sup>. Antibiotic cocktail-treated mice showed changes in *s\_Uniformis*, the *Lachnospiraceae* family and the genera of *Parabacteroides* and *Ruminococcus*<sup>52</sup>. Treatment with anastrozole demonstrated an increase in *Roseburia*, which are butyrate-producing bacteria that can metabolize dietary fibers and exhibit anti-inflammatory effects in the gut<sup>51</sup>. Anastrozole also reduced intestinal and systemic inflammation, improved intestinal barrier function and alleviated cognitive deficits<sup>51</sup>. Another study investigated the effect of FDA-approved medication for AD on intestinal properties in mice. The acetylcholine esterase inhibitors donepezil, rivastigmine and galantamine had no effect on fecal bacteria viability, while a high dose of memantine led to a reduced biofilm formation of *E. coli*. Furthermore, the acetylcholinesterase inhibitors prolonged the colonic propulsion time and memantine increased calcium influx in enteric neurons. Taken together, these results indicate that all FDA-approved drugs for AD could potentially affect different intestinal properties and thereby also the microbiome<sup>53</sup>.

## LIMITATIONS

The literature with regard to the role of the microbiota-gut-brain axis, PD and AD is getting more attention in recent years. However, the currently available studies do have some limitations. Firstly, most studies were performed in animal models and therefore the transferability of the results to a human setting should be carefully considered, since the microbiota composition differs between animals and humans. Secondly, most studies report data from smaller groups and the results are mostly descriptive without mentioning a clear effect size. Finally, the few clinical studies that have been conducted report promising outcomes, but more translational and clinical studies in this domain are eagerly awaited.

## CONCLUSIONS

In this review, we summarized the original research from April 2020 to March 2021 investigating the mechanisms behind microbiota-gut-brain alterations in neurodegenerative disorders such as PD and AD and the effect of modulating the microbiota-gut-brain axis as a potential new therapeutic target. Mechanistic studies pointed out specific associations between the gut microbiota composition on the one hand and gastrointestinal functions or pathophysiological properties of AD or PD on the other hand. An overview of the different microbial alterations in PD and AD models is given in Figure 1. Moreover, a panel of gut microbial markers was put forward as a potential interesting new diagnostic biomarker for PD. Remarkably, studies with regard to AD observed gender-related associations and demonstrated the presence of microbial changes before the onset of typical AD symptoms. The administration of probiotics, prebiotics, supplements, classic medication and alternative therapies showed interesting outcomes with beneficial effects on motor deficits, cognitive impairment, neurotoxicity, pathological lesions in the brain, A $\beta$  deposition (AD), gut microbiota dysbiosis, inflammation (central/systemic/intestinal) and intestinal barrier dysfunction. Some specific effects on the gut microbiota composition seem to play an important role in the amelioration of the pathophysiology of PD and AD such as a decrease in *Clostridiales*, an improvement of the *Bacteroidetes* to *Firmicutes* ratio (increased *Bacteroidetes*, decreased *Firmicutes*) and an increase of *Lactobacillus* and SCFA. The effects of different interventions on the microbiota-gut-brain axis are summarized in table 1 for PD and table 2 for AD. These promising results are a major step forward towards the search for new therapeutic targets for PD and AD. However, most studies are performed in preclinical animal models and therefore more translational studies are eagerly awaited to be able to evaluate the clinical potential of these new targets for the management of PD and AD.



**Figure 1.** Summary of the microbial changes seen in animal models and human studies of Parkinson's and Alzheimer's disease.

**TABLE 1. SUMMARY OF THE EFFECTS OF DIFFERENT INTERVENTIONS IN PD MODELS ON THE MICROBIOTA-GUT-BRAIN AXIS.**

Intervention	Study group	Microbiome	Gut functions	CNS/Brain	Reference
<b>Probiotics</b> <i>Clostridium butyricum</i>	MPTP mouse model	<i>Alistipes</i> ↓ <i>Odoribacter</i> ↓ <i>Prevotellaceae</i> ↓ <i>Akkermansia</i> ↑ <i>Verrucomicrobiaceae</i> ↑		Motor function ↑ Neurotoxicity ↓	Sun et al 2021
<i>Lactobacillus plantarum</i> PS128	MPTP mouse model	<i>Firmicutes/Bacteroidetes</i> ↓ <i>Enterobacteriaceae</i> ↓		Motor function ↑ Neurotoxicity ↓	Liao et al 2020
<i>Bifidobacterium breve</i> strain A1	MPTP mouse model			Cognitive function ↑	Ishi et al 2021
Fecal microbiota transplantation (FMT)	Manganese-exposed rat model			Neurotoxicity ↓ β-amyloid ↓ Tau protein ↓ Hippocampal degeneration & necrosis ↓	Wang et al 2020
<i>Enterococcus faecalis</i>	MPTP + probenecid mouse model	<i>Enterococcus</i> ↑ <i>Escherichia</i> ↑ <i>Lactobacillus</i> ↑ <i>Pseudomonas</i> ↑ <i>Shigella</i> ↑		Dopamine ↑ PD symptoms ↓	Wang et al 2021
VSL#3	LPS + paraquat mouse model	<i>Streptococcaceae</i> ↑		PD symptoms =	Dwyer et al 2021
<b>Prebiotics</b> Fisetin	MPTP mouse model	<i>Bacillaceae</i> ↓ <i>Bifidobacteriaceae</i> ↓ <i>Enterobacteriaceae</i> ↓ <i>Escherichia</i> ↓ <i>Shigella</i> ↓ <i>Lachnospiraceae</i> ↑ <i>Eubacterium</i> ↑ <i>Marvinbryantia</i> ↑		Neurotoxicity ↓	Chen et al 2020

**CONTINUED**

**TABLE 1 (CONTINUED). SUMMARY OF THE EFFECTS OF DIFFERENT INTERVENTIONS IN PD MODELS ON THE MICROBIOTA-GUT-BRAIN AXIS.**

Intervention	Study group	Microbiome	Gut functions	CNS/Brain	Reference
<b>Prebiotics (continued)</b> Propionate or FFAR3-agonist AR420626	6-hydroxydopamine mouse model		Neurotoxicity ↓		Hou et al 2021
Brown seaweed polysaccharide of polymannuronic acid	MPTP mouse model	<i>Lactobacillus</i> ↓ <i>Turicibacter</i> ↓ <i>Coprocooccus</i> ↑ <i>Ruminocooccus</i> ↑	Inflammation ↓ Intestinal barrier ↑ SCFA ↑	Motor function ↑ Neurotoxicity ↓ Dopamine ↑ Striatal neurotransmitters ↑ Inflammation ↓ Blood brain barrier ↑	Dong et al 2020
<b>Supplements</b> Hua-Feng-Dan and 70 Wei-Zhen-Zhu-Wan (Rannasangpei)	MPTP + LPS mouse model	<i>Clostridaceae</i> ↓ <i>Methanobacteriaceae</i> ↓ <i>Pronicromonosporaceae</i> ↓ <i>Verrucomicrobiaceae</i> ↓		Motor function ↑ Brain lesions ↓	Hu et al 2020
Korean red ginseng	MPTP mouse model	<i>Akkermansia</i> ↓ <i>Ruminocooccus</i> ↓ <i>Verrucomicrobiaceae</i> ↓ <i>Eubacterium</i> ↑		Motor function ↑ Brain lesions ↓	Jeon et al 2021
Osteocalcin	6-hydroxydopamine mouse model	Propionate-producing gut microbiota ↑		Motor function ↑ Dopamine ↑	Hou et al 2021
<b>Other</b> Acupuncture	MPTP mouse model	<i>Alistipes</i> ↑ <i>Bacteroides xyloxyticus</i> ↑ <i>Clostridium aerotolerans</i> ↑ <i>Lachnoclostridium</i> ↑ <i>Pseudoclostridium</i> ↑ <i>Rikenellaceae</i> ↑ <i>Roseburia faecis</i> ↑ <i>Vallitaleaceae</i> ↑		Motor function ↑ Dopamine ↑ Anxiety ↓	Jang et al 2020

The interventions that were studied include probiotics, prebiotics, supplements and acupuncture. The effects observed on the microbiota-gut-brain axis include the increase or decrease of specific microbial strains, a decrease in intestinal inflammation, an improved intestinal barrier function, an increase in SCFA, improvement of typical PD-related features (e.g., motor function, neurotoxicity, brain lesions) and beneficial effects on the expression levels of specific neurotransmitters (e.g., dopamine) and proteins (e.g.,  $\beta$ -amyloid and tau-protein). FFAR3 = free fatty acid receptor 3; MPTP = 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine; LPS = lipopolysaccharides; PD = Parkinson's Disease; SCFA = short-chain fatty acids.

**TABLE 2. SUMMARY OF THE EFFECTS OF DIFFERENT INTERVENTIONS IN AD MODELS ON THE MICROBIOTA-GUT-BRAIN AXIS.**

Intervention	Study group	Microbiome	Gut functions	CNS/Brain	Reference
<b>Probiotics</b> <i>Bifidobacterium longum</i> 1714	APP/PS1 double transgenic mice			$\beta$ -amyloid ↓ Microglia activation ↓ Pro-inflammatory cytokines ↓	Wu et al 2020
<i>Bifidobacterium longum</i> BORI <i>Bifidobacterium bifidum</i> BGN4	Healthy 65+ volunteers	<i>Allisonella</i> ↓ <i>Clostridiales</i> ↓ <i>Eubacterium</i> ↓ <i>Prevotellaceae</i> ↓		Mental flexibility test and stress score ↑ BDNF ↑	Kim et al 2021
Lactic acid bacteria strains	Transgenic GMR-A $\beta$ 42 <i>Drosophila melanogaster</i> animal model	<i>Wolbachia</i> ↓ <i>Acetobacter</i> ↑ <i>Stenotrophomonas</i> ↑		Malformation of eye structures ↓	Liu et al 2020
VSL#3	App <sup>NL-G-F</sup> mice	<i>Actinobacteria</i> ↑ <i>Verrucomicrobia</i> ↑ <i>Bacteroidetes/Firmicutes</i> =	Inflammation ↓ Intestinal barrier ↑	$\beta$ -amyloid ↓ Pro-inflammatory cytokines ↓ Gliosis levels ↑	Kaur et al 2020
Fecal microbiota transplantation	Case report AD patient with <i>Clostridium difficile</i> infection			AD symptoms ↓	Azan et al 2020
<b>Prebiotics</b> R13 (7,8-Dihydroxy-flavone prodrug)	5XFAD mouse model	<i>Lactobacillus salivarius</i> ↑	Intestinal barrier ↑	$\beta$ -amyloid ↓ Oxidative stress ↓	Chen et al 2020
yeast $\beta$ -glucans	A $\beta_{1-42}$ -induced mice	<i>Alistipes</i> ↓ <i>Anaerotruncus</i> ↓ <i>Mucispirillum</i> ↓ <i>Oscillibacter</i> ↓ <i>Rikenella</i> ↓ <i>Bacteroidetes/Firmicutes</i> ↑ <i>Bifidobacterium</i> ↑ <i>Desulfovibrio</i> ↑ <i>Lactobacillus</i> ↑ <i>Saccharibacteria</i> ↑	SCFA ↑	Cognitive function ↑ Brain insulin resistance ↑	Xu et al 2020

**CONTINUED**

**TABLE 2 (CONTINUED). SUMMARY OF THE EFFECTS OF DIFFERENT INTERVENTIONS IN AD MODELS ON THE MICROBIOTA-GUT-BRAIN AXIS.**

Intervention	Study group	Microbiome	Gut functions	CNS/Brain	Reference
<b>Supplements</b> Poria cocos	APP/PS1 double transgenic mice	<i>Bacteroidetes/ Firmicutes</i> ↑ <i>Bacteroidaceae</i> ↓ <i>Cyanobacteria</i> ↓ <i>Deferribacteraceae</i> ↓ <i>Enterobacteriaceae</i> ↓ <i>Lactobacillaceae</i> ↓ <i>Lachnospiraceae</i> ↓ <i>Proteobacteria</i> ↓ <i>Ruminococcaceae</i> ↓ <i>Rikenellaceae</i> ↓		Cognitive function ↑ β-amyloid ↓	Sun et al 2021
Salidroside	SAMP8 mice	<i>Clostridiales</i> ↓ <i>Streptococcaceae</i> ↓ <i>Bacteroidetes/ Firmicutes</i> ↑	Intestinal barrier ↑	Cognitive function ↑ β-amyloid ↓ Pro-inflammatory cytokines ↓ Microglial activation ↓	Xie et al 2020
Quercetin-3-O-glucuronide	Aβ <sub>1-42</sub> -induced mice	<i>Bacteroidetes/ Firmicutes</i> ↑	SCFA ↑	Cognitive function ↑ β-amyloid ↓ Brain insulin signaling and resistance ↑	Xu et al 2021
Tetragonia tetragonioides Kuntze	Aβ <sub>25-35</sub> -induced rats	<i>Clostridiales</i> ↓ <i>Erysipelotrichales</i> ↓ <i>Desulfovibrionales</i> ↓ <i>Bacteroidales</i> ↑ <i>Lactobacilales</i> ↑		Cognitive function ↑ β-amyloid ↓ Brain insulin signaling and resistance ↑	Kim et al 2020
Camellia oil	Aluminium chloride-treated rats	<i>Lactobacilales</i> ↑		Cognitive function ↑ β-amyloid ↓ Pro-inflammatory cytokines ↓ AD-related proteins (APP, BACE1, TAU-5) ↓ Antioxidant enzyme levels ↑ Autophagy-related proteins (Atg5, Beclin-1, LC3II) ↑	Weng et al 2020

**CONTINUED**

**TABLE 2 (CONTINUED). SUMMARY OF THE EFFECTS OF DIFFERENT INTERVENTIONS IN AD MODELS ON THE MICROBIOTA-GUT-BRAIN AXIS.**

Intervention	Study group	Microbiome	Gut functions	CNS/Brain	Reference
<b>Supplements (continued)</b>					
Trimethylamine N-oxide	3xTg mouse model			AD symptoms ↑	Govindarajulu et al 2020
Wheat amylase trypsin inhibitors	5XFAD mouse model	<i>Bacteroidetes/Firmicutes</i> ↓ <i>Bifidobacterium</i> ↓		AD symptoms ↑	Dos Santos Guilherme et al 2020
<b>Medication</b>					
Anastrozole	APP/PS1 double transgenic mice	<i>Roseburia</i> ↑	Inflammation ↓ Intestinal barrier ↑	β-amyloid ↓ Inflammation ↓ Cognitive function ↑	Wang et al 2020
Antibiotic cocktail	APP/PS1 double transgenic mice	<i>s_Uniformis</i> ↑ <i>Lachnospiraceae</i> ↑ <i>Parabacteroides</i> ↓ <i>Ruminococcus</i> ↓		β-amyloid ↓	Dodiya et al 2020
Acetylcholine esterase inhibitors	Mice	Fecal bacteria viability =	Colonic propulsion time ↑		Nguyen et al 2021
Memantine	Mice	<i>E. coli</i> biofilm ↓	Enteric neuron properties ↑		Nguyen et al 2021

The interventions that were studied include probiotics, prebiotics, supplements and medication. The effects observed on the microbiota-gut-brain axis include the increase or decrease of specific microbial strains, a decrease in intestinal inflammation, an improved intestinal barrier function, an increase in SCFA, improvement of typical AD-related features (e.g., cognitive function, brain insulin signaling and resistance) and beneficial effects on the expression levels of specific proteins (e.g., β-amyloid) and pro-inflammatory cytokines. AD = Alzheimer's Disease; SCFA = short-chain fatty acids; APP = amyloid-β precursor protein; BACE1 = β-secretase 1; Atg5 = autophagy-related 5; LC3II = Microtubule-associated proteins 1A/1B light chain 3B; BDNF = brain-derived neurotrophic factor.

## Conflict of interest

The authors have no competing interests.

## REFERENCES

1. Martin CR, Osadchiy V, Kalani A, Mayer EA. The Brain-Gut-Microbiome Axis. *Cell Mol Gastroenterol Hepatol* 2018; 6: 133-148.
2. Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet* 2021; 363: 1783-1793.
3. Li W, Zhao Q, Wang J, Wang Y, Wen T. Dcf1 deletion presents alterations in gut microbiota of mice similar to Parkinson's disease. *Biochem Biophys Res Commun* 2020; 529: 1137-1144.
4. Rosario D, Bidkhorji G, Lee S, Bedarf J, Hildebrand F, Le Chatelier E, Uhlen M, Ehrlich SD, Proctor G, Wüllner U, Mardinoglu A, Shoaie S. Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson's disease. *Cell Rep* 2021; 34: 108807.
5. Unger MM, Spiegel J, Dillmann KU, Grundmann D, Philippeit H, Bürmann J, Faßbender K, Schwiertz A, Schäfer KH. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls. *Parkinsonism Relat Disord* 2016; 32: 66-72.
6. Huang T, Shi H, Xu Y, Ji L. The gut microbiota metabolite propionate ameliorates intestinal epithelial barrier dysfunction-mediated Parkinson's disease via the AKT signaling pathway. *Neuroreport* 2021; 32: 244-251.
7. Shin C, Lim Y, Lim H, Ahn TB. Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease. *Mov Disord* 2020; 35: 1021-1027.
8. Li P, Killinger BA, Ensink E, Beddows I, Yilmaz A, Lubben N, Lamp J, Schilthuis M, Vega IE, Woltjer R, Pospisilik JA, Brundin P, Brundin L, Graham SF, Labrie V. Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease. *Metabolites* 2021; 11: 29.
9. Zhu Y, Huan F, Wang J, Xie X, Yu G, Wang X, Jiang L, Gao R, Xiao H, Ding H, Wang J. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induced Parkinson's Disease in Mouse: Potential Association between Neurotransmitter Disturbance and Gut Microbiota Dysbiosis. *ACS Chem Neurosci* 2020; 11: 3366-3376.
10. Vascellari S, Melis M, Cossu G, Melis M, Serra A, Palmas V, Perra D, Oppo V, Fiorini M, Cusano R, Morelli M, Manzin A, Barbarossa IT. Genetic variants of TAS2R38 bitter taste receptor associate with distinct gut microbiota traits in Parkinson's disease: a pilot study. *Int J Biol Macromol* 2020; 165: 665-674.
11. Bhattarai Y, Si J, Pu M, Ross OA, McLean PJ, Till L, Moor W, Grover M, Kandimalla KK, Margolis KG, Farrugia G, Kashyap PC. Role of gut microbiota in regulating gastrointestinal dysfunction and motor symptoms in a mouse model of Parkinson's disease. *Gut Microbes* 2021; 13: 1866974.
12. Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N, Foulger LH, Mackenzie M, Huan T, Finlay BB, Appel-Cresswell S. Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease. *Mov Disord* 2020; 35: 1208-1217.
13. Feng YK, Wu QL, Peng YW, Liang FY, You HJ, Feng YW, Li G, Li XJ, Liu SH, Li YC, Zhang Y, Pei Z. Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. *J Neuroinflammation* 2020; 17: 347.
14. Cannon T, Sinha A, Trudeau LE, Maurice CF, Gruenheid S. Characterization of the intestinal microbiota during Citrobacter rodentium infection in a mouse model of infection-triggered Parkinson's disease. *Gut Microbes* 2020; 12: 1-11.
15. Qian Y, Yang X, Xu S, Huang P, Li B, Du J, He Y, Su B, Xu LM, Wang L, Huang R, Chen S, Xiao Q. Gut metagenomics-derived genes as potential biomarkers of Parkinson's disease. *Brain* 2020; 143: 2474-2489.
16. Pietrucci D, Teofani A, Unida V, Cerroni R, Biocca S, Stefani A, Desideri A. Can Gut Microbiota Be a Good Predictor for Parkinson's Disease? A Machine Learning Approach. *Brain Sci* 2020; 10: 242.
17. Sun J, Li H, Jin Y, Yu J, Mao S, Su KP, Ling Z, Liu J. Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson's disease via gut microbiota-GLP-1 pathway. *Brain Behav Immun* 2021; 91: 703-715.
18. Liao JF, Cheng YF, You ST, Kuo WC, Huang CW, Chiou JJ, Hsu CC, Hsieh-Li HM, Wang S, Tsai YC. Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease. *Brain Behav Immun* 2020; 90: 26-46.
19. Ishii T, Furuoka H, Kaya M, Kuhara T. Oral Administration of Probiotic Bifidobacterium breve Improves Facilitation of Hippocampal Memory Extinction via Restoration of Aberrant Higher Induction of Neuropsin in an MPTP-Induced Mouse Model of Parkinson's Disease. *Biomedicines* 2021; 9: 167.
20. Wang H, Yang F, Xin R, Cui D, He J, Zhang S, Sun Y. The gut microbiota attenuate neuroinflammation in manganese exposure by inhibiting cerebral NLRP3 inflammasome. *Biomed Pharmacother* 2020; 129: 110449.
21. Wang Y, Tong Q, Ma SR, Zhao ZX, Pan LB, Cong L, Han P, Peng R, Yu H, Lin Y, Gao TL, Shou JW, Li XY, Zhang XF, Zhang ZW, Fu J, Wen BY, Yu JB, Cao X, Jiang JD. Oral berberine improves brain dopa/dopamine levels to ameliorate Parkinson's disease by regulating gut microbiota. *Signal Transduct Target Ther* 2021; 6: 77.
22. Dwyer Z, Chaquin M, Landrigan J, Ayoub K, Shail P, Rocha J, Childers CL, Storey KB, Philpott DJ, Sun H, Hayley S. The impact of dextran sodium sulphate and probiotic pre-treatment in a murine model of Parkinson's disease. *J Neuroinflammation* 2021; 18: 20.
23. Chen TJ, Feng Y, Liu T, Wu TT, Chen YJ, Li X, Li Q, Wu YC. Fisetin Regulates Gut Microbiota and Exerts Neuroprotective Effect on Mouse Model of Parkinson's Disease. *Front Neurosci* 2020; 14: 549037.
24. Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, Kong XK, Wang SM, Gong YL, Yang YY, Tao B, Sun LH, Zhao HY, Guo XZ, Wang WQ, Ning G, Gu YY, Li ST, Liu JM. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease. *Microbiome* 2021; 9: 34.

25. Dong XL, Wang X, Liu F, Liu X, Du ZR, Li RW, Xue CH, Wong KH, Wong WT, Zhao Q, Tang QJ. Polymannuronic acid prevents dopaminergic neuronal loss via brain-gut-microbiota axis in Parkinson's disease model. *Int J Biol Macromol* 2020; 164: 994-1005.
26. Hu AL, Song S, Li Y, Xu SF, Zhang F, Li C, Liu J. Mercury sulfide-containing Hua-Feng-Dan and 70W (Ranna-sangpei) protect against LPS plus MPTP-induced neurotoxicity and disturbance of gut microbiota in mice. *J Ethnopharmacol* 2020; 254: 112674.
27. Jeon H, Bae CH, Lee Y, Kim HY, Kim S. Korean red ginseng suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced inflammation in the substantia nigra and colon. *Brain Behav Immun* 2021.
28. Jang JH, Yeom MJ, Ahn S, Oh JY, Ji S, Kim TH, Park HJ. Acupuncture inhibits neuroinflammation and gut microbial dysbiosis in a mouse model of Parkinson's disease. *Brain Behav Immun* 2020; 89: 641-655.
29. Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer's disease. *Alzheimer's disease. Nat Rev Dis Primers* 2015; 1: 15056..
30. Cuervo-Zanatta D, Garcia-Mena J, Perez-Cruz C. Gut Microbiota Alterations and Cognitive Impairment Are Sexually Dissociated in a Transgenic Mice Model of Alzheimer's Disease. *J Alzheimers Dis* 2021. doi: 10.3233/JAD-201367. Online ahead of print.
31. Wu J, Zhu X, Lin H, Chen Z, Tang H, Wang Y. Gender differences in the bile acid profiles of APP/PS1 transgenic AD mice. *Brain Res Bull* 2020; 161: 116-126.
32. Ferretti MT, Iulita MF, Cavedo E, Chiesa PA, Schumacher Dimech A, Santuccione Chadha A, Baracchi F, Girouard H, Misoch S, Giacobini E, Depypere H, Hampel H. Sex differences in Alzheimer disease - the gateway to precision medicine. *Nat Rev Neurol* 2018; 14: 457-469.
33. Li Z, Zhu H, Guo Y, Du X, Qin C. Gut microbiota regulate cognitive deficits and amyloid deposition in a model of Alzheimer's disease. *J Neurochem* 2020; 155: 448-461.
34. Chen Y, Fang L, Chen S, Zhou H, Fan Y, Lin L, Li J, Xu J, Chen Y, Ma Y, Chen Y. Gut Microbiome Alterations Precede Cerebral Amyloidosis and Microglial Pathology in a Mouse Model of Alzheimer's Disease. *Biomed Res Int* 2020; 2020: 8456596.
35. Wei S, Peng W, Mai Y, Li K, Wei W, Hu L, Zhu S, Zhou H, Jie W, Wei Z, Kang C, Li R, Liu Z, Zhao B, Cai Z. Outer membrane vesicles enhance tau phosphorylation and contribute to cognitive impairment. *J Cell Physiol* 2020; 235: 4843-4855.
36. Chi H, Cao W, Zhang M, Su D, Yang H, Li Z, Li C, She X, Wang K, Gao X, Ma K, Zheng P, Li X, Cui B. Environmental noise stress disturbs commensal microbiota homeostasis and induces oxi-inflammation and AD-like neuropathology through epithelial barrier disruption in the EOAD mouse model. *J Neuroinflammation* 2021; 18: 9.
37. Wu Q, Li Q, Zhang X, Ntim M, Wu X, Li M, Wang L, Zhao J, Li S. Treatment with Bifidobacteria can suppress A $\beta$  accumulation and neuroinflammation in APP/PS1 mice. *Peer J* 2020; 8: e10262.
38. Kim CS, Cha L, Sim M, Jung S, Chun WY, Baik HW, Shin DM. Probiotic Supplementation Improves Cognitive Function and Mood with Changes in Gut Microbiota in Community-Dwelling Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. *J Gerontol A Biol Sci Med Sci* 2021; 76: 32-40.
39. Liu G, Tan FH, Lau SA, Jaafar MH, Chung FY, Azzam G, Liong MT, Li Y. Lactic acid bacteria feeding reversed the malformed eye structures and ameliorated gut microbiota profiles of *Drosophila melanogaster* Alzheimer's Disease model. *J Appl Microbiol* 2020. doi: 10.1111/jam.14773. Online ahead of print.
40. Kaur H, Nagamoto-Combs K, Golovko S, Golovko MY, Klug MG, Combs CK. Probiotics ameliorate intestinal pathophysiology in a mouse model of Alzheimer's disease. *Neurobiol Aging* 2020; 92: 114-134.
41. Hazan S. Rapid improvement in Alzheimer's disease symptoms following fecal microbiota transplantation: a case report. *J Int Med Res* 2020; 48: 300060520925930.
42. Chen C, Ahn EH, Kang SS, Liu X, Alam A, Ye K. Gut dysbiosis contributes to amyloid pathology, associated with C/EBP $\beta$ /AEP signaling activation in Alzheimer's disease mouse model. *Sci Adv* 2020; 6: eaba0466.
43. Xu M, Mo X, Huang H, Chen X, Liu H, Peng Z, Chen L, Rong S, Yang W, Xu S, Liu L. Yeast  $\beta$ -glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in A $\beta$ (1-42)-induced AD-like mice. *Int J Biol Macromol* 2020; 161: 258-270.
44. Sun Y, Liu Z, Pi Z, Song F, Wu J, Liu S. *Poria cocos* could ameliorate cognitive dysfunction in APP/PS1 mice by restoring imbalance of A $\beta$  production and clearance and gut microbiota dysbiosis. *Phytother Res* 2021. doi: 10.1002/ptr.7014. Online ahead of print.
45. Xie Z, Lu H, Yang S, Zeng Y, Li W, Wang L, Luo G, Fang F, Zeng T, Cheng W. Salidroside Attenuates Cognitive Dysfunction in Senescence-Accelerated Mouse Prone 8 (SAMP8) Mice and Modulates Inflammation of the Gut-Brain Axis. *Front Pharmacol* 2020; 11: 568423.
46. Xu M, Huang H, Mo X, Zhu Y, Chen X, Li X, Peng X, Xu Z, Chen L, Rong S, Yang W, Liu S, Liu L. Quercetin-3-O-Glucuronide Alleviates Cognitive Deficit and Toxicity in A $\beta$ (1-42)-Induced AD-Like Mice and SH-SY5Y Cells. *Mol Nutr Food Res* 2021; 65: e2000660.
47. Kim DS, Ko BS, Ryuk JA, Park S. *Tetragonia tetragonioides* Protected against Memory Dysfunction by Elevating Hippocampal Amyloid- $\beta$  Deposition through Potentiating Insulin Signaling and Altering Gut Microbiome Composition. *Int J Mol Sci* 2020; 21: 2900.
48. Weng MH, Chen SY, Li ZY, Yen GC. Camellia oil alleviates the progression of Alzheimer's disease in aluminum chloride-treated rats. *Free Radic Biol Med* 2020; 152: 411-421.
49. Govindarajulu M, Pinky PD, Steinke I, Bloemer J, Ramesh S, Kariharan T, Rella RT, Bhattacharya S, Dhanasekaran M, Suppiramaniam V, Amin RH. Gut Metabolite TMAO Induces Synaptic Plasticity Deficits by Promoting Endoplasmic Reticulum Stress. *Front Mol Neurosci* 2020; 13: 138.
50. Dos Santos Guilherme M, Zevallos VF, Pesi A, Stoye NM, Nguyen VTT, Radyushkin K, Schwiertz A, Schmitt U, Schuppan D, Endres K. Dietary Wheat Amylase Trypsin Inhibitors Impact Alzheimer's Disease Pathology in 5xFAD Model Mice. *Int J Mol Sci* 2020; 21.

51. Wang Y, An Y, Ma W, Yu H, Lu Y, Zhang X, Wang Y, Liu W, Wang T, Xiao R. 27-Hydroxycholesterol contributes to cognitive deficits in APP/PS1 transgenic mice through microbiota dysbiosis and intestinal barrier dysfunction. *J Neuroinflammation* 2020; 17: 199.
52. Dodiya HB, Frith M, Sidebottom A, Cao Y, Koval J, Chang E, Sisodia SS. Synergistic depletion of gut microbial consortia, but not individual antibiotics, reduces amyloidosis in APPS1-21 Alzheimer's transgenic mice. *Sci Rep* 2020; 10: 8183.
53. Nguyen VTT, Sallbach J, Dos Santos Guilherme M, Endres K. Influence of Acetylcholine Esterase Inhibitors and Memantine, Clinically Approved for Alzheimer's Dementia Treatment, on Intestinal Properties of the Mouse. *Int J Mol Sci* 2021; 22: 1015.